A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia–reperfusion injury
Fabio Fiordaliso(University of Milan), Roberto Latini(Mario Negri Institute for Pharmacological Research), Ivan Cuccovillo(Mario Negri Institute for Pharmacological Research), Lidia Staszewsky(Mario Negri Institute for Pharmacological Research), Eleonora Carlo(University of Milan), Pietro Ghezzi(Brighton and Sussex Medical School), Manuela Mengozzi(Mario Negri Institute for Pharmacological Research), Mirko Doni(New York Medical College), Thomas R. Coleman(University of Messina), Rossella Tonelli(New York Medical College), Stefano Chimenti(University of Milan), Anthony Cerami(Araim Pharmaceuticals (United States)), Antonio Bai(University of Milan), Michael Brines(Northwell Health)
Cited by 224
Related Papers
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k
Clinical Relevance of Biomarkers of Oxidative Stress
|Antioxidants and Redox Signaling|2015|906